CA242 Antibody & Antigen | GI Cancer CLIA IVD

Name: CA242 Antibody & Antigen Panel (S01-CA242-4M + S01-CA242-1H + S02-CA242-W602)
Brand: Sekbio

Product Overview

What is CA242? — A Definition for IVD Developers

CA242 (Cancer Antigen 242) is a sialylated carbohydrate epitope displayed on mucin-type glycoproteins circulating in serum. It is structurally related to, but antigenically distinct from, the sialyl-Lewis-a epitope recognized by the widely used tumor marker CA19-9, and the two are synthesized through different glycosylation pathways in gastrointestinal adenocarcinoma tissue.

In a published comparative study of 181 gastrointestinal tumor patients (colon n=50, hepatocellular carcinoma n=86, pancreatic n=27, gastric n=18) and 28 age-matched controls, serum CA242 (cut-off >20 U/mL) was the most sensitive single marker for colon cancer alongside CEA, both reaching 48.0% sensitivity at 100% specificity, and combining CEA with CA242 raised colon cancer sensitivity to 72.0% — the highest combination result in the study. In pancreatic cancer, CA242 alone reached only 29.6% sensitivity, and adding CA242 to CA19-9 did not improve on CA19-9's 70.4% sensitivity alone, a finding the authors attribute to prior reports of cross-reactive behavior between CA242 and CA19-9 antibodies. CA242 sensitivity was lower still in hepatocellular carcinoma (7.7%) and gastric cancer (11.1%) (Attallah AM et al., Int J Cancer Res 2006;2(1):50-56).

For IVD developers, Sekbio supplies a complete CA242 raw material set: S01-CA242-4M (mouse monoclonal antibody) and S01-CA242-1H (recombinant humanized monoclonal antibody), both epitope-matched to reference clone C242, alongside S02-CA242-W602 — a native CA242 antigen purified directly from human colon carcinoma tissue for calibrator and standard-curve use. Sekbio's in-house CLIA/ELISA method comparison against the CanAg reference ELISA shows R²=0.985 across the full clinical range (n=125), confirming the antibody pair's readiness for kit development. All products are manufactured under an ISO 13485 quality management system with full batch traceability, and are designed to pair with Sekbio's existing CA19-9 and CEA antibody pairs for combined GI cancer panels.

Sialylated Mucin Epitope Colorectal Cancer Marker ISO 13485 Manufacturer Native Colon-Carcinoma Antigen

Antibody Specifications (S01-CA242-4M)

Product NameMouse Anti-CA242 mAb

Catalog No.S01-CA242-4M

EpitopeSimilar to reference clone C242

Host / IsotypeMouse IgG1

Purity>90% (SEC-HPLC)

FormatPurified, Liquid (typ. 4.27–4.51 mg/mL)

Buffer20mM PB + 150mM NaCl, pH 7.4

Storage2–8°C

PlatformsLFA / CLIA / ELISA

Complete Product Catalog

CA242 Panel — All Products

Mouse and humanized antibody clones plus a native colon-carcinoma-derived antigen for complete CA242 sandwich immunoassay development.

Catalog No.	Product Name	Type	Purity	Intended Use	Storage
S01-CA242-4M	Mouse Anti-CA242 Monoclonal Antibody	mAb (Mouse IgG1)	>90% SEC-HPLC	LFA / CLIA / ELISA	2–8°C
S01-CA242-1H	Recombinant Humanized Anti-CA242 Monoclonal Antibody	mAb (Human IgG1)	>90% SEC-HPLC	LFA / CLIA / ELISA	2–8°C
S02-CA242-W602	Human Cancer Antigen 24-2 (Native, Human Colon Carcinoma)	Native Antigen	Per CoA	Calibrator / Standard	−20°C±5°C

S01-CA242-4M / -1H: buffer 20mM PB + 150mM NaCl, pH 7.4. S02-CA242-W602: 1000 KU/mL in PBS pH 7.4 with 0.05% sodium azide preservative, avoid repeated freeze-thaw. MOQ 1 mg (antibody) / inquire (antigen). Contact info@sekbio.com for datasheets, CoA, and bulk pricing.

Verified Performance

Method Correlation vs. CanAg Reference ELISA

In-house paired-sample comparison of the Sekbio CA242 antibody pair against the CanAg CA242 ELISA reference method.

1 Full Clinical Range Correlation

Across 125 paired serum samples spanning 1–288.5 U/mL, Sekbio's CA242 assay showed excellent agreement with the CanAg reference ELISA: linear regression y=1.0458x−1.3146, R²=0.985 — a near-ideal 1:1 slope across the full clinical range, including markedly elevated values.

Method comparison scatter plot of Sekbio CA242 assay versus CanAg ELISA across the full clinical range, n=125, 1 to 288.5 U/mL, showing linear regression y = 1.0458x - 1.3146 and R-squared 0.985

Sekbio CA242 (U/mL) vs. CanAg ELISA (U/mL), n=125, full range 1–288.5 U/mL. y=1.0458x−1.3146, R²=0.985.

2 Low-Range Correlation Near the Clinical Cut-Off

Because the diagnostic decision for CA242 is made around the >20 U/mL cut-off, Sekbio also validated correlation specifically in the low-concentration zone: 105 paired samples spanning 1–39.6 U/mL gave y=0.9582x+0.1349, R²=0.9475 — confirming accuracy where a false positive/negative call matters most.

Method comparison scatter plot of Sekbio CA242 assay versus CanAg ELISA in the low concentration range, n=105, 1 to 39.6 U/mL, showing linear regression y = 0.9582x + 0.1349 and R-squared 0.9475

Sekbio CA242 (U/mL) vs. CanAg ELISA (U/mL), n=105, low range 1–39.6 U/mL. y=0.9582x+0.1349, R²=0.9475.

3 Published Clinical Sensitivity Across GI Cancers

Independent published data (cut-off >20 U/mL) show CA242's sensitivity varies substantially by GI cancer type, with the strongest performance in colon cancer, especially when combined with CEA.

GI Cancer Type	CA242 Alone	CEA + CA242 Combined	Notes
Colon Cancer (n=50)	48.0%	72.0%	Most sensitive single & combined marker in the study
Pancreatic Cancer (n=27)	29.6%	37.0%	CA19-9 alone (70.4%) remains preferred; CA242 does not add to CA19-9
Gastric Cancer (n=18)	11.1%	22.0%	Non-significant increase; low sensitivity overall
Hepatocellular Carcinoma (n=86)	7.7%	7.7%	AFP remains the preferred HCC marker

¹ Source: Attallah AM, Al-Ghawalby NA, Abdel Aziz AAF, El-Sayed EA, Tabll AA, El-Waseef AM. "Clinical Value of Serum CEA, CA 19-9, CA 242 and AFP in Diagnosis of Gastrointestinal Tract Cancers." Int J Cancer Res 2006;2(1):50-56. Specificity was 100% for CA242 and CEA at these cut-offs against the study's 28 controls.

Why Choose Sekbio CA242 Panel

Performance Advantages for GI Cancer Panel Development

A validated antibody pair plus native antigen, benchmarked directly against an established commercial reference method.

Validated Against CanAg Reference ELISA

In-house correlation of R²=0.985 (n=125, full range) and R²=0.9475 (n=105, low range near the >20 U/mL cut-off) against the CanAg CA242 ELISA gives developers a documented performance baseline before kit development begins.

Native Colon-Carcinoma-Derived Antigen

S02-CA242-W602 is a native CA242 antigen purified from human colon carcinoma tissue rather than a recombinant fragment, giving calibrators and standard curves the same glycosylation pattern as circulating patient antigen.

Humanized Variant for HAMA Reduction

S01-CA242-1H provides the same C242-like epitope specificity as the mouse clone S01-CA242-4M but with a humanized IgG1 framework, reducing interference from human anti-mouse antibodies (HAMA) in CLIA analyzer applications.

Evidence-Based Panel Design

Published data show CA242 adds the most value paired with CEA in colorectal cancer (72.0% combined sensitivity), while offering little incremental benefit over CA19-9 alone in pancreatic cancer — helping developers target CA242 to the panel where it performs best.

High Purity >90% SEC-HPLC

Both S01-CA242-4M and S01-CA242-1H are affinity-purified to >90% by SEC-HPLC, reducing non-specific serum matrix binding that would otherwise raise background signal near the >20 U/mL clinical cut-off.

OEM-Ready Global Supply

ISO 13485-compliant manufacturing in Shenzhen, China, with full Certificate of Analysis documentation, MOQ 1 mg for R&D, and gram-scale OEM supply for production-volume CLIA kit manufacturing.

Use Cases

CA242 Panel Applications in IVD Development

CA242 antibody and antigen panel for gastrointestinal cancer diagnostics and combination tumor marker panel development.

Colorectal Cancer Panel Development

CA242 combined with CEA is the strongest-performing pairing in published data (72.0% sensitivity, up from 48.0% for either marker alone), making it the priority use case for developers building a colorectal cancer CLIA or ELISA panel. See our CEA Antibody Pair for the companion CEA raw material.

Pancreatic Cancer Adjunct Testing

While CA19-9 remains the marker of first choice for pancreatic cancer (70.4% sensitivity alone), some developers still include CA242 in broader GI cancer panels for completeness; published data show it adds little incremental sensitivity when combined with CA19-9 in this indication.

Combination GI Cancer Panels

Because CA242 performance varies substantially by GI cancer type, IVD developers combine it selectively with CEA, CA19-9, and AFP — see our CA19-9 Antibody Pair and AFP Antibody Pair — on a single CLIA platform to match each marker to its strongest indication.

OEM CLIA Kit Manufacturing & Regulatory Support

Sekbio's ISO 13485-certified manufacturing, full CoA documentation, and in-house CanAg method correlation data support OEM CLIA kit manufacturers preparing CE IVD and other regulatory submissions. Visit our Products page for the full oncology raw material portfolio, or contact us to discuss OEM supply.

FAQ

Frequently Asked Questions — CA242 Antibody & Antigen Panel

Technical and commercial questions from IVD R&D engineers and procurement teams.

What is CA242 and why is it used as a tumor marker?

CA242 (Cancer Antigen 242) is a sialylated carbohydrate epitope carried on mucin-type glycoproteins, structurally related to but distinct from the sialyl-Lewis-a epitope recognized by CA19-9. CA242 is elevated in the serum of patients with colorectal, pancreatic, and other gastrointestinal malignancies. In a published comparative study of 181 gastrointestinal tumor patients and 28 controls, CA242 (cut-off >20 U/mL) showed 48.0% sensitivity and 100% specificity for colon cancer — matching CEA as the most sensitive single marker tested — and combining CEA with CA242 raised colon cancer sensitivity to 72.0% (Attallah AM et al., Int J Cancer Res 2006;2(1):50-56).

What catalog numbers are in Sekbio's CA242 panel?

Sekbio's CA242 panel includes three products: S01-CA242-4M (Mouse anti-CA242 monoclonal antibody, Mouse IgG1, epitope similar to reference clone C242), S01-CA242-1H (recombinant humanized anti-CA242 monoclonal antibody, Human IgG1, same C242-like epitope), and S02-CA242-W602 (native CA242 antigen purified from human colon carcinoma tissue, 1000 KU/mL). Contact info@sekbio.com for datasheets, Certificate of Analysis, and MOQ pricing.

How well does Sekbio's CA242 assay correlate with the CanAg reference ELISA?

In Sekbio's in-house method comparison against the CanAg CA242 ELISA reference method, the full clinical range (n=125 paired samples, 1–288.5 U/mL) gave the regression y=1.0458x−1.3146 with R²=0.985. In the clinically sensitive low range (n=105 paired samples, 1–39.6 U/mL, spanning the >20 U/mL cut-off), the regression was y=0.9582x+0.1349 with R²=0.9475, confirming strong agreement at the concentrations most relevant to a positive/negative clinical call.

Is CA242 more useful in colorectal cancer or pancreatic cancer?

Published data indicate CA242 is most useful in colorectal cancer, where it matches CEA as the most sensitive single marker (48.0% sensitivity, 100% specificity) and where combining CEA with CA242 raises sensitivity to 72.0%. In pancreatic cancer, CA242 alone showed only 29.6% sensitivity in the same study, and combining CA19-9 with CA242 did not improve on CA19-9's 70.4% sensitivity alone — consistent with earlier reports that CA242 and CA19-9 antibodies show cross-reactive behavior in pancreatic disease. CA19-9 therefore remains the marker of first choice for pancreatic cancer, with CA242 adding the most value in colorectal cancer panels (Attallah AM et al., Int J Cancer Res 2006;2(1):50-56).

What are the MOQ and storage conditions for CA242 products?

MOQ is 1 mg per antibody clone for R&D evaluation, with OEM production quantities from 10 mg to gram scale available. S01-CA242-4M and S01-CA242-1H (purity >90% by SEC-HPLC) are stable at 2–8°C in 20mM PB + 150mM NaCl, pH 7.4. The native antigen S02-CA242-W602 (1000 KU/mL in PBS pH 7.4 with 0.05% sodium azide) should be stored at −20±5°C and protected from repeated freeze/thaw cycles. Certificate of Analysis accompanies every lot.

Can Sekbio supply CA242 antibody and antigen for OEM CLIA kit development and regulatory submissions?

Yes. Sekbio is an ISO 13485-certified manufacturer supplying the matched CA242 mouse and humanized antibody pair plus native colon-carcinoma-derived antigen, with full batch documentation, Certificate of Analysis, and in-house CanAg method correlation data to support CE IVD and other regulatory submissions. Sekbio also supplies the companion CA19-9 and CEA antibody pairs for combination gastrointestinal cancer panels. Contact info@sekbio.com to request datasheets or OEM pricing. Visit our Platforms page for antibody development and custom antigen expression services.

CA242 Antibody & Antigen Panel